News Overview



FatiAbGen Co. Ltd., established in Korea in 2020, engineers best in class antibodies, tailored for multiple modalities such as ADCs, bi-specifics, and Car-T, to address difficult targets in oncology and immunology. We focus on the highest unmet need indications.

We have an active collaboration strategy with world-class partners, always with the goal to develop the best products faster and to de-risk programs as much as possible by the time they reach IND.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.